Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers

NCT00001693 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Colorectal Neoplasm
Hereditary Nonpolyposis

Interventions

DRUG: Celecoxib (SC-58635)

Sponsor

National Cancer Institute (NCI)